Trial reportClinical lung cancer2017
Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
Trial report in Clinical lung cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Respiratory adverse effects in patients treated with immune checkpoint inhibitors in combination with radiotherapy: a systematic review and meta-analysis.Radiation oncology (London, England) · 2024Pooled it
- Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic.Frontiers in oncology · 2022Pooled it
- Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review).Oncology letters · 2025Review
- Article
- Combination of immunotherapy and whole-brain radiotherapy on prognosis of patients with multiple brain metastases: A retrospective cohort study.Open life sciences · 2025Article
- Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy.Biomarker research · 2024Review
- Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges.Cancer medicine · 2023Review
- Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence.Current oncology (Toronto, Ont.) · 2022Review
- Radiotherapy combined with immunotherapy: the dawn of cancer treatment.Signal transduction and targeted therapy · 2022Review
- Review
- Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial.Journal of oncology · 2022Article
- The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2021Review
- New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer.World journal of clinical oncology · 2021Review
- The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances.International journal of molecular sciences · 2021Review
- Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.International journal of molecular sciences · 2021Review
- PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.Cancer chemotherapy and pharmacology · 2021Article
- Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study.Frontiers in oncology · 2021Article
- Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non-Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study.International journal of general medicine · 2021Article
- Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).British journal of cancer · 2020Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 10 institutions in 1 country.
Funding
Abstract
Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.